WHI-P154

CAS No. 211555-04-3

WHI-P154 ( JAK3 Inhibitor II; Janus-Associated Kinase 3 Inhibitor II )

Catalog No. M13364 CAS No. 211555-04-3

WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 32 In Stock
5MG 50 In Stock
10MG 79 In Stock
25MG 167 In Stock
50MG 314 In Stock
100MG 510 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    WHI-P154
  • Note
    Research use only, not for human use.
  • Brief Description
    WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.
  • Description
    WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.
  • Synonyms
    JAK3 Inhibitor II; Janus-Associated Kinase 3 Inhibitor II
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR; JAK3; Src; VEGFR
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    211555-04-3
  • Formula Weight
    376.20
  • Molecular Formula
    C16H14BrN3O3
  • Purity
    >98%(HPLC)
  • Solubility
    DMSO: 75 mg/mL (199.36 mM)
  • SMILES
    OC1=CC=C(NC2=C3C=C(OC)C(OC)=CC3=NC=N2)C=C1Br
  • Chemical Name
    2-Bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.O'Donoghue ML, et al. J Thromb Thrombolysis. 2012 Jul;34(1):36-43.
molnova catalog
related products
  • Naquotinib

    Naquotinib (ASP-8273) is a potent, irreversible, mutant-selective inhibitor of EGFR.

  • Mobocertinib

    Mobocertinib is a potent ?inhibitor of epidermal growth factor receptor (EGFR) and an antineoplastic agent.

  • Oritinib

    Oritinib is an inhibitor of EGFR with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM for EGFR (wt), EGFR (L858R), EGFR (L861Q), EGFR (L858R/T790M), EGFR (d746-750), EGFR (d746-750/T790M), respectively. Oritinib can be used in studies about the treatment of non-small cell lung cancer.